These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 11895052)

  • 1. Broth microdilution and E-test for determining fluoroquinolone activity against Streptococcus pneumoniae.
    Kays MB; Graff MA
    Ann Pharmacother; 2002 Mar; 36(3):416-22. PubMed ID: 11895052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoroquinolone susceptibility, resistance, and pharmacodynamics versus clinical isolates of Streptococcus pneumoniae from Indiana.
    Kays MB; Denys GA
    Diagn Microbiol Infect Dis; 2001 Aug; 40(4):193-8. PubMed ID: 11576793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
    LaPlante KL; Rybak MJ; Tsuji B; Lodise TP; Kaatz GW
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test.
    Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S
    Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activity and pharmacodynamics of five fluoroquinolones against clinical isolates of Streptococcus pneumoniae.
    Kays MB; Conklin M
    Pharmacotherapy; 2000 Nov; 20(11):1310-7. PubMed ID: 11079279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interpretive categorical accuracy of fluoroquinolone reference broth microdilution MIC results when testing Streptococcus pneumoniae: selection of a surrogate testing agent.
    Sader HS; Koeth LM; Poupard JA; Jones RN
    Diagn Microbiol Infect Dis; 2008 Dec; 62(4):460-3. PubMed ID: 18990533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
    Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and etest method validation. Quality Control Study Group.
    Jones RN; Johnson DM; Erwin ME; Beach ML; Biedenbach DJ; Pfaller MA
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):91-8. PubMed ID: 10354857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of pharmacokinetic/pharmacodynamic (PK/PD) parameters of gatifloxacin on its bactericidal activity and resistance selectivity against clinical isolates of Streptococcus pneumoniae.
    Ebisu H; Kishii R; Takei M; Fukuda H
    J Infect Chemother; 2003 Sep; 9(3):210-4. PubMed ID: 14513387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
    Zelenitsky SA; Ariano RE; Iacovides H; Sun S; Harding GK
    J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae.
    Jorgensen JH; Weigel LM; Swenson JM; Whitney CG; Ferraro MJ; Tenover FC
    Antimicrob Agents Chemother; 2000 Nov; 44(11):2962-8. PubMed ID: 11036007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
    Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication.
    Lister PD
    Antimicrob Agents Chemother; 2002 Jan; 46(1):69-74. PubMed ID: 11751113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Coyle EA; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1654-9. PubMed ID: 11353608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents.
    Browne FA; Bozdogan B; Clark C; Kelly LM; Ednie L; Kosowska K; Dewasse B; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3815-24. PubMed ID: 14638489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data.
    Kowalski RP; Yates KA; Romanowski EG; Karenchak LM; Mah FS; Gordon YJ
    Ophthalmology; 2005 Nov; 112(11):1987. PubMed ID: 16183128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of resistance to gatifloxacin and moxifloxacin in Streptococcus pneumoniae with the VITEK 2 instrument.
    Jorgensen JH; Crawford SA; McElmeel LM; Whitney CG
    J Clin Microbiol; 2004 Dec; 42(12):5928-30. PubMed ID: 15583344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.